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ABSTRACT 
This bio-computational study aimed to explore phytochemicals derived from Indonesian 
plants which inhibited the mineralocorticoid receptor (MR) for cardiovascular diseases 
treatment. A total of 516 phytochemicals was used in this study which was derived from the 
HerbalDB database and screened with Lipinski Rule of Five. Three dimensional structure of 
MR was obtained from a protein data bank (access code 3VHU) and the structure of  aldosterone 
antagonists (spironolactone and eplerenone) as standard ligand was obtained from the ZINC 
database (ZINC03977913 and ZINC72187491) respectively. MR-standar ligand binding 
complexes were validated using AutoDock Vina 1.1.2 software three times. Interaction between 
MR and phytochemicals was molecularly dock with the same software and visualized using 
Chimera 1.9 software. Spironolactone had -9.5 kcal/mol docking score and MR binding site at 
Gln776, Arg817, and Cys942. Whereas -9.7 kcal/mol docking score was observed in eplerenone and 
it had binding site at Arg817 and Thr945. There were six phytochemicals with lower binding score 
againts MR than the standards but only Sojagol interacted with MR at Gln776 and Arg817 
residues. More over, Sojagol had a lower molecular size (336.338 Da) compared with the 
standards and was commonly found in mung beans. In conclusion, Sojagol might become in silico 
antagonist of aldosterone.  
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In recent years, cardiovascular and circulatory 
diseases have become the world health burden 
and the leading causes of death worldwide. In 
2013, there were up to 54 million deaths globally 
and cardiovascular diseases were attributable to 
32% of these deaths (17 million).(1) Moreover, 
80% of cardiovascular diseases mortality occurs in 
low-income and middle-income countries. It is 
estimated that cardiovascular diseases will give 
rise to 23.6 millions of death in 2030.(2) 
Aldosterone has been known for many years as 
an endogenous hormone that plays an important 
role in the pathogenesis of heart disease.(3)(4) 
Growing evidence had indicated that aldosterone 
was involved in the progression of end-organ 
damage since it induced vascular smooth muscle 
hypertrophy, vascular matrix impairment 
(remodelling) and endothelial dysfunction.(5)(6) 
Inhibition of aldosterone and other 
mineralocorticoid steroids to the MR has been 
demonstrated to have beneficial therapy in 
various cardiovascular disease.(7) Hence, 
aldosterone antagonist has become a new 
therapeutic agent, based on its sodium retention 
properties in the management of cardiovascular 
diseases.(8)(9) 
Spironolactone is firstly generated as MR 
antagonist. It is able to inhibit not only the MR 
but also other families of steroid receptor. 
Therefore, it is not surprised if long term 
administration of spironolactone has unwanted 
effects like progestational and antiandrogenic 
activities.(3)  
Virtual screening which uses molecular docking 
methods is one of the most effective ways to 
explore new agents or phytochemicals as a novel 
candidate of aldosterone antagonist.(10) 
Molecular docking is a computer program that can 
predict the complex structure of two molecules in 
silico efficiently.(11) So, this study aimed to 
explore phytochemicals of Indonesian herbal 
plants which were able to interact with 
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mineralocorticoid receptor (MR) and potentially 
developed as a new aldosterone antagonist. 
 
MATERIAL AND METHODS 
 
Protein preparation 
 Preparation of MR protein was performed 
using AutoDockVina program 1.1.2 version.(12) 
Three dimensional structure of MR was 
downloaded from Protein Data Bank 
(http://www.rcsb.org/pdb/) with access code 
3VHU. This MR protein was crystallized with 
spironolacton and had 2.11 Å diffraction pattern. 
In addition, spironolacton was interacted with 
MR at Gln776, Arg817, and Cys942 residues.(13) 
Before running the molecular docking, 
spironolactone and water were removed from the 
MR structure. Hydrogen was then added to MR in 
order to increase polarity in the binding pocket. 
After that, grid box was made by selection of some 
amino acid residues that surrounded the binding 
pocket. Hence, three binding site of 
spironolactone to the MR had to be located in the 
center of grid box.  
 
Standard ligand preparation 
 Aldosterone was used as the standard ligand 
agonist of MR while spironolactone and 
eplerenone became the aldosterone standard 
antagonists. Their three dimensional structures 
were obtained from ZINC database 
(zinc.docking.org) with access code 
ZINC03830183, ZINC03977913 and 
ZINC72187491 respectively. They were saved in 
*mol2 and *sdf format. Validation of MR-
standard ligand interaction was molecularly 
docked with AutoDock Vina 1.1.2 software three 
times to obtaine the binding energy (Table 1). 
Visualisation of MR-standard ligand interaction 
was done using Chimera software (version 1.9, 
The Resource for Biocomputing, Visualization, 
and Informatics, University of California) (Fig.1). 
Their binding sites were compared with the 
binding sites of Hasui’s study.(13) The validation 
results were then used as the reference to explore 
candidates of aldosterone antagonist. 
 
Phytochemical preparation 
 Phytochemicals of Indonesian herbal plants 
were obtained from HerbalDB data base which 
was Indonesian herbal data base and developed 
by Department of Pharmacy, Universitas 
Indonesia http://herbaldb.farmasi.ui.ac.id/. The 
phytochemical structures were downloaded from 
a public data base at 
https://pubchem.ncbi.nlm.nih.gov/. All 
phytochemicals of Indonesian herbal plants were 
then screened using Lipinski’s rule of five 
criteria(14) and 517 phytochemicals were used as 
the research samples. All selected phytochemicals 
were modified and prepared using PyRx program. 
They finally saved in *.pdbqt format file. 
   
 
 
Table 1. Validation results of MR interacted with aldosterone, spironolactone or eplerenone 
  
Validation  
1 
 
Validation  
2 
 
Validation  
3 
Average of 
binding 
energy 
(kcal/mol) 
Binding site 
Aldosterone 
(ZINC03830183) -9.3 
 
-9.3 
 
-9.3 
 
-9.3  Asn770, Gln776, Arg817 
Spironolactone 
(ZINC03977913) -9.5 
 
-9.6 
 
-9.5 
 
-9.5 Gln776, Arg817, Cys942* 
Eplerenone 
(ZINC72187491) -9.7 
 
-9.7 
 
-9.7 
 
-9.7 Arg817 and Thr945 
*The first two binding sites were the same as binding sites of Hasui’s work 
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(A)  (B) 
 
(C) 
Fig 1. MR-standard ligand binding complexes were visualized using Chimera 1.9 
software.  
A). Aldosterone interacted with MR at Asn770 , Gln776 and Arg 817 residues. B). Spironolactone 
interacted with MR at at Gln776, Arg817 and Cys942 residues while (C) eplerenone interacted 
with MR at Arg817 and Thr945. 
 
Docking and visualisation of herbal 
phytochemical 
 A total of 517 selected phytochemicals was 
molecularly docked with MR using AutoDockVina 
1.1.2 program to analyze their binding energy. 
Molecular interaction of MR and phytochemicals 
was then visualized using Chimera 1.9 program. 
MR-phytochemical binding complexes which had 
lower binding energy than standard ligand 
antagonist and had similar binding sites were 
considered as a new candidate of MR antagonist. 
 
RESULTS 
 
Validation of standard ligands 
Figure 1 showed that binding sites of MR 
agonist and antagonist. Aldosterone interacted 
with the MR at Asn770, Gln776 and Arg817 
residues. Whist, MR antagonist (spironolactone) 
bound to MR at Gln776, Arg817 and Cys942 
residues. These binding sites were different from 
the previous study which Asn770 was substituted 
with Cys942 residue. Arg817 and Thr945 residues 
were found in Eplerenone-MR interaction.    
 
Molecular docking between MR and 
phytochemicals of Indonesian herbal plants  
From 517 phytochemicals which full filled 
Lipinski’s criteria, only 6 phytochemicals had 
lower binding energy than MR standard agonist 
and antagonists (Table 2).  Progesterone had the 
lowest binding energy (-11.5 kcal/mol) whilst   
strychnine had the highest binding energy (-9.8 
kcal/mol). Eurycomalactone and sojagol shared 
similar binding energy. In terms of binding site, 
there was only sojagol that had similar binding 
sites (Gln776 and Arg817) to aldosterone and 
spironolactone (Figure 1 and Table 1). Other 
phytochemicals interacted with MR only at one 
amino acid residue (Asn770, Leu810, Arg817, or 
Cys942).  Additionally, molecular weight of all 
phytochemicals was lower than molecular weight 
of MR agonist and antagonists. The lowest 
molecular weight was observed in gentisin 
(258.226 Da) while the highest molecular weight 
was eurycomalactone (348.390 Da). Strychnine 
had molecular weight as similar  as  sojagol 
(approximately 335 Da).   
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Docking visualisation between MR and 
Sojagol 
Figure 2 showed that sojagol occupied the MR 
binding pocket as similar as spironolactone except 
Cys942. Sojagol bound to the MR at Gln776 and 
Arg817 residues and had similar conformation to 
spironolactone. 
 
Table 2. Result of docking between phytochemical of Indonesian herbal plant with MR 
Phytochemical name 
Average of 
binding energy 
(kcal/mol) Binding site 
Molecular 
weight  
(Da) 
Aldosterone -9.3 Asn770, Gln776, Arg817 360.45 
Spironolactone -9.5 Gln776, Arg817, Cys942 416.583 
Eplerenone -9.7 Arg817, Thr945 414.498 
Progesterone -11.5 Arg817 314.461 
Strychnine -9.8 Asn770 334.412 
Eurycomalactone -10.2 Cys942 348.390 
Strigol -10.6 Cys942 346.374 
Gentisin -9.9 Leu810 258.226 
Sojagol -10.1 Gln776, Arg817 336.338 
DISCUSSION 
 
In this study, we found some differences of 
binding sites between aldosterone /spironolactone 
and MR using different docking methods. 
Aldosterone is the endogenous steroid hormone 
that occupies the ligand binding domain (LBD) of 
MR at Asn770, Gln776 and Arg817 residues. Our 
results differ from other studies that reported 
aldosterone interacted with MR at Asn770, Ser767, 
Cys942, Thr945 and Glu955 residues.(15) Asn770 
residue is importantly required for stable binding 
to activate MR by which recruits some 
coactivators.(8) The two remaining residues 
(Gln776 and Arg817) were reported to play an 
important role in stabilization of hydrogen bound 
with the MR.(9) Whereas, Ser767, Cys942, Thr945 
and Glu955 residues are also needed to make 
hydrogen bond with activation function-2 of MR 
in helix 3 and 10.(15) 
Spironolactone is passive MR antagonist 
because this compound has labile interaction with 
the LBD of MR and prevent recruitment of 
coactivators.(16) Spironolactone occupies Gln776 
and Arg817 residues of MR binding pocket to block 
aldosterone-MR interaction. In our study, 
spironolactone also binds to the MR at Cys942 
residue to make a lipophilic bond and to restrict 
the volume of binding space.(8) In contrast to our 
results, Hasui and co-workers reported that 
spironolactone has Asn770 instead of Cys942 
residue to interact with MR. Asn770 is useful for 
binding stability and partial MR agonist or 
antagonist.(15) Further investigation is required 
to solve these different results. 
From this bio-computaional study, we have 
demonstrated that sojagol was a new candidate of 
in silico MR antagonist regarding to binding 
energy, binding sites and molecular weight. A 
lower binding energy observed in sojagol will has 
a higher affinity to interact with the MR 
 
 
 
 
 
 
 
 
 
 
A 
 
 
b 
  
 
 
 
 
 
 
B                                       
Fig 2. A. MR-Spironolactone binding complexes were visualized using Chimera 1.9. 
B. Overlay of MR-spironolacton/Sojagol binding complexes. Green colour was 
spironolactone and Sojagol was yellow. Black circles were designated binding sites.    
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compared with the standard MR antagonists. In 
addition to binding affinity, the lower energy also 
stabilizes sojagol-MR binding complexes. In 
general, binding score in molecular docking 
programs is calculated by summing up all 
molecular interactions like hydrophobic, 
hydrogen, van de Walls, electrostatic and 
solvation effect.(17)(18) Therefore, stronger 
molecular interaction will has lower binding 
energy and more stable ligand binding complex. 
In our study, sojagol has two residues (Gln776 
and Arg817) which are very important for 
interaction with the LBD of MR. Although sojagol 
does not have Asn770 binding site, it will give a 
beneficial effect which lead to inactivation of 
MR.(8) This natural compound is different from 
some synthetic compounds that created by 
Hasui’s lab center. The synthetic compounds bind 
to the MR at Asn770, Gln776 and Arg817 residues 
that they probably have side effects as same as 
spironolactone for long term use although their 
selectivity is higher than spironolactone.  
The next advantage of sojagol properties is its 
molecular weight. Sojagol has lower molecular 
weight compared with the existing MR 
antagonists. Lower molecular size of drug 
molecules will increase their absorption and 
bioavaibility in blood circulation.(19)  
Sojagol is a secondary metabolite which is 
found in Phaseolus radiates plant (mung bean). 
One study has reported that administration of 
mung bean extracts lowers blood pressure in mice 
and exerts anti-inflammatory and antioxidant 
effects.(20) Another study indicated that mung 
bean extracts suppressed inflammation-induced 
by lipopolysaccharide in macrophage cell line.(21) 
Moreover, cardioprotective effect appears in rat 
model with cardiac damage which was given 
mung bean extracts. In the end of treatment. It 
significantly improved the integrity of heart 
tissues.(22) Overall, sojagol may potentially to be 
developed as a new MR antagonist. In conclusion, 
six phytochemicals have lower binding energy 
and molecular size than spironolactone and 
eplerenone but only sojagol has similar binding 
sites to the MR antagonist. Sojagol might become 
in silico MR antagonist. Further investigation 
should be performed to investigate whether or not 
sojagol has MR antagonist activity. 
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